Angelini Pharma
Angelini is committed to identifying health solutions with a prevalent focus on the areas of Central Nervous System (CNS), including pain, and Rare Diseases. The Company is also a leading player in the Consumer Health sector,
News & publications
-
Angelini Pharma acquires Arvelle Therapeutics
This acquisition will propel Angelini Pharma into a leading European player, well positioned to address the needs of patients with different CNS and mental disorders.
-
Gabriele Ghirlanda is the new Global Access & Value Director of Angelini Pharma
In his role, Ghirlanda reports directly to CEO Pierluigi Antonelli and joins the Executive Leadership Team, the Company's Steering Committee.
-
The second issue of Aptitude Magazine
In this issue, new stories and news, a focus on our commitment on mental health and our digital transformation, with the voices of the protagonists of our change.
Media center
Core areas
-
Rare Diseases
A disease is defined as rare when its prevalence, that is the number of cases present at a given time in a given population, does not exceed a certain threshold. In the European Union this threshold is set at 0.05% of the population.
-
Mental Health
The burden of mental health conditions is on the rise globally and major depression, bipolar mood disorder and schizophrenia are among the 10 leading causes of disability worldwide.
-
Consumer Health
Angelini has always recognized and supported the empowerment of patients even in the therapeutic approach of responsible self-medication, in keeping with the fundamental criteria of appropriate drug utilisation.
DISCOVER THE SELECTION OF ARTICLES FROM
From Pipeline to health aids
-
-
Sites
All sites use the most advanced technologies, with automatic control and supervision systems. Analysis and quality control, right from the raw material stage, are particularly stringent.
-
Pipeline
The R&D mission is built on the dynamic pipelini concept, where each project can be partially or fully developed in-house or through collaborative partnership
COLLABORATION
Angelini Pharma Worldwide
